07:00 , Jul 16, 2012 |  BioCentury  |  Finance

Asset value arbitrage

The Vontobel Group is looking to take Swiss biotech fund BB Biotech AG private. That would allow both the Swiss bank and shareholders of BB Biotech to cash in on a longstanding discrepancy between the...
07:00 , Sep 28, 2009 |  BioCentury  |  Finance

Ebb & Flow

The pair of life sciences companies on IPO road shows may give investors and other companies clues on the opening of an IPO window. Profitable plasma-derived protein company Talecris Biotherapeutics Inc. may price this week,...
08:00 , Jan 7, 2008 |  BioCentury  |  Finance

Mollified by mid-caps

Fund managers are looking to 2008 with more optimism than one might expect from people who saw their portfolios struggle against the benchmarks last year. While some of the optimism may be associated with 2008...
08:00 , Jan 9, 2006 |  BC Week In Review  |  Company News

Bellevue Asset Management other news

Bellevue changed its name to Swissfirst Asset Management. Bellevue Asset Management , Kusnacht, Switzerland   Business: Other  ...
08:00 , Jan 9, 2006 |  BioCentury  |  Finance

Ebb & Flow

Pacific Growth Equities last week unveiled plans to avoid what it thinks is the increasing commoditization of sellside research. The firm rolled out its Sector Sales department to provide unpublished investment ideas to the firm's...
08:00 , Dec 12, 2005 |  BioCentury  |  Finance

Ebb & Flow

Even after this month's blowup at Rigel (RIGL), when Phase II data for its R112 allergic rhinitis candidate did not pan out, VCs who led the company's PIPE in April 2003 still look to have...
07:00 , Apr 18, 2005 |  BioCentury  |  Finance

Ebb & Flow

As the sign says, "objects in the rear view mirror are closer than they appear." On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and...
08:00 , Feb 28, 2005 |  BioCentury  |  Finance

Ebb & Flow

Last week's venture rounds by Switzerland's Speedel and Italy's Newron might suggest the two are taking themselves off the list of potential European IPO candidates for this year, as both returned to the private markets...
07:00 , Jul 26, 2004 |  BioCentury  |  Finance

Ebb & Flow Focus

German sector watchers breathed a sigh of relief last week after Epigenomics AG became the first biotech company to list in Germany since February 2001. But investors still say it would be better for quality...
08:00 , Jan 19, 2004 |  BioCentury  |  Finance

Ebb & Flow

Investors look to the JPMorgan conference to kick off the year for life sciences, and last week's event in San Francisco did not disappoint. The nearly 5,500 "official" attendees made for packed halls and stuffed...